

Building Bridges: Strengthening the Industrial Radiopharmaceutical Ecosystem in Oslo



Time	Session	Lead
08:30-09:00	Registration and mingling	OITL
09:00-09:10	Welcome by OITL – Focus of the seminar	Thor Audun Saga, Managing Director, Norwegian Medical Cyclotron Center AS
09:10-11:00	Status of the preclinical radiopharmaceutical development - Industry partners in different stages of development	Industry
09:10-09:20	GE HealthCare FASTlab™ — automated, GMP ready synthesis of established and emerging molecular imaging tracers	Dag Erlend Olberg, Senior Radiochemist, GE HealthCare
09:20-09:30	Preclinical Development of ¹⁸ F CD8 PET as an Imaging Immuno Diagnostic Biomarker	Matilde Forni, Senior Nonclinical Scientist, GE HealthCare
09:30-09:45	The development of ARAspheres (actinium-225-RGD-alginate nanoparticles) for radioligand therapy of glioblastoma	Michael Dornish, Chief Scientific Officer, Blue Wave Therapeutics AS
09:45-10:00	The future of radiopharmaceuticals: alpha radioligand therapy with the ²¹² Pb isotope	Tanja Aarvak, PhD, Director, Program Management, Artbio AS
10:00-10:15	Building the next generation radioligand therapy (RLT) platform	Erlend E. Myrnes, CMC Development Director, Actithera
10:15-10:30	Development of novel targeted radiation therapeutics at Nuclithera	Ada Repetto-Llamazares, Chief Scientific Officer, NucliThera AS
10:30-10:45	TBD	Tor Espen Stav-Noraas, Co-founder, Node Pharma AS
10:45-11:00	Developing the next generation of targeted radionuclide therapy for the benefit of cancer patients	Jenny Karlsson, Senior Director, Targeted Radiopharmaceuticals, Bayer AS
11:00-11:15	Break	
11:15-12:15	Strengthening preclinical infrastructure for translational radiopharmacy	
11:15-11:25	Comparative Medicine Infrastructure at IMB, UiO: Enabling Preclinical and Translational Research	Erle Linnea Fevåg, Administrative Manager, Department of comparative medicine-UiO
11:25-11:45	Connecting Discovery to Clinic: OITL's Role in Oslo's Translational Radiopharma Ecosystem.	Bent Wilhelm Schoultz, R&D director; Christoffer Wikborg, Operational Director, Norwegian Medical Cyclotron Center
11:45-12:00	The establishing and operation of a GMP manufacturing plant for a radiopharmaceutical IMP	Kristine Lofthus, Chief Production Officer, Oncoinvent AS

Building Bridges: Strengthening the Industrial Radiopharmaceutical Ecosystem in Oslo



12:00-12:15	Agilera's contribution to the Norwegian ecosystem as a CDMO	Bente Tange Harbø, Sector director, Radiopharmaceutical R&D, Agilera Pharma AS
12:15-13:15	Lunch	
13:15-13:45	Panel Discussion - Overcoming preclinical bottlenecks in radiopharmaceutical development	GE HealthCare, Thor Medical, Artbio, Node Pharma, Nuclithera, NMS/OITL
13:45-14:00	Talent information – Introduction to NNRC	Professor, Sunniva Siem, Department of Physics, University of Oslo
14:00-14:15	Facilitators in the radiopharmaceutical ecosystem in Oslo	OCCI
14:15-14:45	Radionuclide availability and access for early-stage research	
14:15-14:30	From stone to cancer therapy	Sindre Hasfjell, Chief Technical Officer (CTO), Thor Medical
14:30-14:45	TBD	Asta Juzeniene, Associate Professor, Biophysics and Medical Physics, University of Oslo
14:45-15:00	Break	
15:00-15:30	Panel Discussion - Industry aspirations: Preclinical dosimetry and clinical translation	Caroline Stokke, Asta, Actithera, Bayer AS
15:30-16:00	Sponsors Presentations	
15:30-15:40	Convenience and reliability with Hidex AMG automated gamma counter for biodistribution studies	Sari Viljanen, Product line manager, Nuclear medicine at Hidex Oy
15:40-15:50	Alpha emitters imaging, dosimetry or workflows for evaluating new compounds	BIOEMTECH
15:50-16:00	MR Solutions Group - Redefining Preclinical Imaging	Angela Mega-Camacho, Applications Team Leader & Sales Support in MR Solutions Group
16:00-16:15	Closing remarks	NMS/OITL and OCCI
16:15-18:00	Pizza & social networking	OITL